John McLaughlin
CIK: 0001203240
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Sonoma Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jul 9, 2026SNOA
Sonoma Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
10K shares- - Jan 2, 2026SNOA
Sonoma Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
10K shares- - Jan 2, 2025SNOA
Sonoma Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
7.5K shares-
1-3 of 3 transactions
About MCLAUGHLIN JOHN
MCLAUGHLIN JOHN (SEC CIK 0001203240) files insider reports with the SEC as Director of Sonoma Pharmaceuticals, Inc. (SNOA).
Signal8 holds 3 ownership filings by MCLAUGHLIN JOHN, all Form 4s, filed between Jan 3, 2025 and Jul 9, 2026. Those filings report 3 transactions, from Jan 2, 2025 to Jul 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MCLAUGHLIN JOHN's filings is in BOULDER, CO.
Recent filings by MCLAUGHLIN JOHN
Other insiders filing for Sonoma Pharmaceuticals, Inc. (SNOA)
- Weigerstorfer Philippe, Director
- Trombly Amy Moss, Chief Executive Officer
- Jacoby Vanessa, Director
- DVONCH JEROME J, Chief Financial Officer
- Dal Poggetto John, Controller
- Birnbaum Jay E, Director